Related references
Note: Only part of the references are listed.Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study
Nobuyuki Miyasaka et al.
Modern Rheumatology (2014)
Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study
V. Madan et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2010)
Clinical Assessment of Tacrolimus Therapy in Lupus Nephritis: One-Year Follow-Up Study in a Single Center
Yukari Asamiya et al.
NEPHRON CLINICAL PRACTICE (2009)
Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis
Yutaka Furukawa et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Multitarget therapy of lupus nephritis: Base hit or home run?
Richard J. Glassock
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Successful treatment of class V+IV lupus nephritis with multitarget therapy
Hao Bao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis
C. -C. Szeto et al.
RHEUMATOLOGY (2008)
Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis
Lionel Couzi et al.
ARTHRITIS AND RHEUMATISM (2007)
A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade
K. C. Tse et al.
LUPUS (2007)
Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study
CC Mok et al.
KIDNEY INTERNATIONAL (2005)
Increase in activated CD8+T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus
P Blanco et al.
ARTHRITIS AND RHEUMATISM (2005)
Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506
M Sugiyama et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2004)
The role of interleukin-10 in systemic lupus erythematosus
L Llorente et al.
JOURNAL OF AUTOIMMUNITY (2003)
Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus
T Kanekura et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil
O Millan et al.
CLINICAL CHEMISTRY (2003)
The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus
SL Walker et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production
HS Jiang et al.
TRANSPLANTATION (2002)
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids)
S Sakuma et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2001)
Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro
S Sakuma et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2001)
FK506 potently inhibits T cell activation induced TNF-α and IL-1β production in vitvo by human peripheral blood mononuclear cells
S Sakuma et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
